Cingulate (CING) Share-based Compensation (2021 - 2026)
Cingulate's (CING) quarterly Share-based Compensation came in at $385965.0 in Q4 2025, up 539.55% YoY from $60349.0 in Q4 2024, and down 62.93% on a QoQ basis from $1.0 million in Q3 2025.
Cingulate (CING) Share-based Compensation (2021 - 2026) Analysis & Trends
Cingulate (CING) has 5 years of Share-based Compensation data on file, last reported at $385965.0 in Q4 2025.
- Quarterly Share-based Compensation rose 539.55% year-over-year to $385965.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.8 million (up 54.77% YoY) and the FY2025 annual result came in at $1.5 million, up 53.07% from the prior year.
- Share-based Compensation eased to $385965.0 in Q4 2025, from $1.0 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $2.1 million in Q4 2021 to a low of $60349.0 in Q4 2024.
- A 5-year average of $507087.0 and a median of $212281.5 in 2022 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation slumped 90.12% — and 2024, when it surged 630.99%.
- Tracing CING's Share-based Compensation over 5 years: stood at $2.1 million in 2021, then tumbled by 90.12% to $206436.0 in 2022, then declined by 25.13% to $154564.0 in 2023, then tumbled by 60.96% to $60349.0 in 2024, then surged by 539.55% to $385965.0 in 2025.
- The last three Share-based Compensation figures came in at $385965.0 (Q4 2025), $1.0 million (Q3 2025), and $357649.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cingulate | 72.85 Mn | 72.85 Mn | - | 362,227.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 362,227.00 |
| Jun 30, 2026 | 362,227.00 |
| Dec 31, 2025 | 385,965.00 |
| Dec 31, 2025 | 385,965.00 |
| Sep 30, 2025 | 1.04 Mn |
| Sep 30, 2025 | 1.04 Mn |
| Mar 31, 2025 | 357,649.00 |
| Mar 31, 2025 | 357,649.00 |
| Dec 31, 2024 | 60,349.00 |
| Dec 31, 2024 | 60,349.00 |
| Sep 30, 2024 | 812,691.00 |
| Sep 30, 2024 | 812,691.00 |
| Jun 30, 2024 | 1.59 Mn |
| Jun 30, 2024 | 1.59 Mn |
| Mar 31, 2024 | 164,575.00 |
| Mar 31, 2024 | 164,575.00 |
| Dec 31, 2023 | 154,564.00 |
| Dec 31, 2023 | 154,564.00 |
| Sep 30, 2023 | 235,251.00 |
| Sep 30, 2023 | 235,251.00 |